The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 9, pp. 1321-1324. DOI 10.1345/aph.1D050
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schatz, R. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schatz, R. A

DRUG INFORMATION ROUNDS

Olanzapine for Psychotic and Behavioral Disturbances in Alzheimer Disease

Robin A Schatz, PharmD

at time of writing, PharmD Student, College of Pharmacy, The University of Toledo, Toledo, OH

Reprints: Robin A Schatz PharmD, 2532 Baneberry Ln., #734, Indianapolis, IN 46268-7755, robinschatz{at}msn.com

OBJECTIVE: To evaluate the efficacy and safety of olanzapine for the treatment of psychotic and behavioral disturbances in Alzheimer disease.

DATA SOURCES: MEDLINE (1966–January 2003) and Science Citation Index searches were performed. Key search terms included olanzapine, Alzheimer(s), and dementia.

DATA SYNTHESIS: Four trials of olanzapine and subsequent post hoc analyses were reviewed. Three trials found a benefit associated with olanzapine use, but a fourth trial did not.

CONCLUSIONS: Olanzapine appears to be effective in treating psychotic and behavioral disturbances associated with Alzheimer disease. However, the most appropriate dose remains to be determined. The benefit of olanzapine therapy must be weighed against the adverse effect profiles of olanzapine and alternative treatment options.

Key Words: Alzheimer disease, dementia, olanzapine

Published Online, June 23, 2003. www.theannals.com, DOI 10.1345/aph.1D050




homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.